# Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

> **NCT04834908** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bharat Serums and Vaccines Limited** · enrollment: 7 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Equine COVID-19 Antiserum
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT04834908
- **Lead sponsor:** Bharat Serums and Vaccines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-27
- **Primary completion:** 2022-05-25
- **Final completion:** 2022-05-25
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Closed as no eligible patient.
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834908, "Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04834908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*